In this section

Clinical

Clinical Trials

Research

Research studies

Clinical trials

Listing updated: 19 April 2024

Trial title
Blood cancer type
Therapy history
Current trial status

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukaemia or Cytotoxic Lymphomas

Lymphoma (at least one prior line)
Recruiting

A Phase Ib/II Open-Label Study of APG2575 in Combination with Novel Therapeutic Regimens in Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light Chain Amyloidosis
  • Relapsed or refractory multiple myeloma
  • Immunoglobulin light chain amyloidosis (AL)
 Relapsed/refractory multiple myeloma or AL amyloidosis previously treated with at least 1 line of prior therapy
 
 Recruiting

Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM)

Relapsed multiple myeloma

 At least 3 prior lines including Pis and IMiDs or at least 2 prior lines if at least one of these lines consisted of 2 or more multiagent regimens
 
 Recruiting
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic
Properties of Orally Administered APG-2575 in Patients with Hematologic Malignancies
 
  • Lymphoplasmocytic lymphoma
  • Mantle cell lymphoma 
  • Relapsed/refractory diffuse large B-cell lymphoma 
  • Waldenstrom's macroglobulinemia
  • Chronic lymphocytic leukaemia
  • Acute myeloid leukaemia
  • Multiple myeloma
  • Any B-cell Non-Hodgkin Lymphoma
 Relapsed, refractory or intolerant to standard therapy Recruiting
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor Myelofibrosis Intermediate-2 or High-risk Myelofibrosis Refractory to JAK Inhibitor Recruiting
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
  • Follicular lymphoma
  • Marginal zone lymphoma
  • Diffuse Large B-Cell Lymphoma
 
 Relapsed/refractory to at least two prior lines of therapy including anti-CD20 antibody and an alkylating agent
 
 Recruiting
A Phase 1a/1b Study of PSB202 in patients with previously treated-, relapsed-, indolent B Cell Malignancies
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Small Lymphocytic Lymphoma
  • Waldenstrom Macroglobulinaemia
  • Chronic Lymphocytic Leukaemia
 Relapsed or refractory to at least two prior lines of therapy Recruiting
A Randomized, 2-Arm, Phase 3 Study Of Elranatamab (PF-06863135) vs Lenalidomide In Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Undergoing Autologous Stem-Cell Transplantation

Newly diagnosed multiple myeloma after autologous stem cell transplantation

 Autologous stem cell transplantation Recruiting
A Phase 3, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab, and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or refractory multiple myeloma

 Relapsed or refractory to 1-2 prior lines of therapy Recruiting
Phase 1/2 study with an open-label dose escalation phase followed by a randomised, double-blind phase of SLN124 in patients with Polycythemia Vera Polycythemia Vera    Recruiting
An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly-Diagnosed Multiple Myeloma  Newly diagnosed multiple myeloma No prior therapy and ineligible for transplant  Recruiting
A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Relapsed/refractory multiple myeloma At least 3 prior lines of therapy  Recruiting
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected
Subjects with Relapsed or Refractory Multiple Myeloma		 Relapsed/refractory multiple myeloma Previous treatment with a proteasome inhibitor, immunomodulatory agent and an anti-CD38 antibody  Recruiting
First-in-human, open label Phase 1/2 study to investigate safety and efficacy of SAR445515, an NK-cell-engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relaped/refractory multiple myeloma (RRMM) and in relapsed/refractory light-chain amyloidosis (RR LCA)
 Relapsed/refractory multiple myeloma and relapsed/refractory light chain amyloidosis Myeloma: at least 2 prior lines of therapy including a proteasome inhibitor, immunomodulatory agent and an anti-CD38 antibody

Amyloidosis: at least 1 prior line of therapy including a proteasome inhibitor
 
  Recruiting
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) Relapsed/refractory multiple myeloma At least 1 prior line of therapy including lenalidomide and an anti-CD38 antibody  Recruiting
International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 parental study Relapsed/refractory multiple myeloma Completed a phase 1, 2 or 3 parental study of isatuximab  Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma or primary mediastinal large B-cell lymphoma Maximum 1 prior line of therapy including an anti-CD30 and anthracycline  Recruiting
 A phase 3, open-label, randomized study to compare the safety and efficacy of Odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, versus investigator’s choice in previously untreated participants with Follicular lymphoma (OLYMPIA-1) Follicular lymphoma  No prior therapies  Recruiting
 A Phase 3, Open label, Randomized Study Comparing the Safety and Efficacy of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3) Diffuse large B-cell lymphoma  No prior therapies  Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Safety and Efficacy of Odronextamab Combined with Lenalidomide Versus Rituximab Combined with Lenalidomide in Relapsed/Refractory Indolent Lymphoma (OLYMPIA-5) Relapsed/refractory follicular lymphoma (grade 1-3a) or marginal zone lymphoma At least 1 prior line of therapy including an anti-CD20 antibody  Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Relapsed/refractory follicular or marginal zone lymphoma Previously received ≥ 1 line of systemic therapy including anti-CD20 agent  Recruiting

You can also find up-to-date information on the following platforms:

  • ClinTrial Refer App – download and add ‘Haematology Clinical Research Network’ and search for “Epworth Healthcare”
  • Cancer Council Victoria - cancervic.org.au/trials and search ‘Epworth Hospital Haematology’

Research studies and clinical data registries - current

The Molecular Oncology and Cancer Immunology (MOCI) pillar of the Centre leads translational, investigator-initiated research in the fields of genomics and cancer immunology. Please contact us if you are interested in taking part in research studies to advance cancer knowledge.

Title

Category

Summary

Key eligibility criteria

strong>Principal Investigator/s (PI)

MOCI (Molecular Oncology and Cancer Immunology) Biobank Study

Investigator-led biobank study

This study collects and stores de-identified patient blood and tissue samples and clinical information for use in future research projects and clinical studies

Individuals with haematological or solid tissue malignancies

Dr CostasYannakou

ThectDNAProject-

Analysis and monitoring of cell free DNA in haematological malignancy

MOCI-guided service in collaboration with molecular haematology laboratory,Peter MacCallum Cancer Centre

This project studies patient biomarkers at various stages of their disease while allowing blood cancer patients to access genomic testing that may help guide treatment options

Individuals with chronic lymphocytic leukemia (CLL), lymphoma and myeloma

 

Dr CostasYannakou

Prof Miles Prince

Dr Piers Blombery

CABL Study: Circulating Tumour DNA (ctDNA) as a Biomarker of Response to Anti-cancer Therapy in

B-cell non-Hodgkin Lymphoma

Observational investigator-led study

This study aims to evaluate the levels of plasma ctDNA before, during and after treatment in patients with B-cell non-Hodgkin lymphoma to assess whether ctDNA levels can be used as a prognostic marker

Individuals with newly diagnosed or relapsed/refractory B-cell non-Hodgkin lymphoma

Dr CostasYannakou

Circulating Tumour DNA as a Biomarker of Tumour Burden in Plasma Cell Dyscrasias (CAMP Study)

 

Observational, investigator-led stud

This study aims to evaluate the levels of plasma ctDNA before, during and after treatment in patients with plasma cell dyscrasia to assess whether ctDNA levels can be used as a prognostic marker

Individuals with newly diagnosed or relapsed/refractory multiple myeloma, solitary plasmacytoma or AL amyloidosis

Dr CostasYannakou

DENEM Study: Detection of Early Neurotoxicity Using Eyelid Movements

Observational investigator-led study in collaboration withOptalert

This study aims to develop methods to classify grades of neurotoxicity in patients undergoing immunotherapyusually associated with neurotoxicity

Individuals with haematological malignancy planned for immunotherapy, chemotherapy or a haematological disorder not receiving anti-cancer therapy

Dr CostasYannakou

Prof Miles Prince

Gailey-Lazarus Snowdome Myeloid Fellowship

Observational investigator-led study in collaboration with the University of Melbourne and Peter MacCallum Cancer Centre

This Fellowship provides options for patients with myelofibrosis through access to clinical trials.
Provide access to unfunded genomic testing for patients with myeloiddisorders, andperform exploratory genomic analyses to investigate the disease mechanisms underlying myeloid disorders.

Individuals with myeloid disorders

Dr Indu Raman

Dr CostasYannakou

Lymphoma and Related Diseases Registries (LaRDR)

Clinical data registry in collaboration with Monash University

This registry records data from Australia and New Zealand on patient diagnosis and treatment to assist in better understanding of factors that influence patient outcomes

Individuals with newly diagnosed non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia(CLL), and related diseases

Prof Miles Prince

ICAN Study: Immunoglobulin use in outcomes in CLL and NHL

Clinical data registry in collaboration with Monash University and funded by the National Blood Authority

This registry is sub-study ofLaRDRthat examines immunoglobulin and antibiotic use and infection data which will help guide clinical practice, plan and deliver cost-effective care for better patient outcomes

Individuals diagnosed with chronic lymphocytic leukemia(CLL) or non-Hodgkin lymphoma that are participating in the LaRDR study

Prof Miles Prince

Myeloma and Related Diseases Registry (MRDR)

Clinical data registry in collaboration with Monash University

This registry collects current clinical practice data from newly diagnosed patients from Australia and the Asia-Pacific region in the hope of driving improvements beneficial to patients

Individuals diagnosed with multiple myeloma, MGUS, plasma cell leukaemia or plasmacytoma

Prof Miles Prince

M1000 – Biobank sub-project of MRDR

Biobank repository of blood samples collaboration with Monash University

This is a sub-study of the MRDR and aims to establish a biobank repository of blood samples from multiple myeloma or MGUS patients for future biomarker studies

Individuals with newly diagnosed multiple myeloma or MGUS

Prof Miles Prince

Opportunistic infections in patients with indolent non-Hodgkin Lymphoma (iNHL) treated with bendamustine +/- anti-CD20 monoclonal antibody

Retrospective data project investigating treated with bendamustine-based regimens

This is a retrospective data project performed by the Australasian Lymphoma Alliance (ALA) which aims to collect real-world data to improve clinical care and practice for lymphoma patients. Through Epworth’s membership, MOCI has contributed data to this research project.

Individuals newly diagnosed and relapsed/refractory patients with indolent NHL or chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Dr CostasYannakou

Incidence, outcomes and treatment strategies for plasmablastic lymphoma in both HIV positive and negative patients in Australia and New Zealand: 20 years of experience

Clinical data collection in collaboration with St Vincent’s Hospital Sydney

Plasmablastic lymphoma is an aggressive disease with poor prognosis. Existing data was collected from patients diagnosed with plasmablastic lymphoma to establish a snapshot of therapeutic practice and outcomes.

Patients diagnosed with plasmablastic lymphoma

Dr CostasYannakou

Factors influencing outcome in Richter’s Transformation; results of a multi-centre retrospective

A multi-centre retrospective study in collaboration with St Vincent’s Hospital Melbourne

This multi-centre retrospective cohort study evaluated outcomes in patients with Richter’s transformation; a subset of lymphoma associated with pre-existing CLL/SLL, known to have poor outcomes and currently, there is a lack of treatment consensus

 

 

Study on Richter’s transformation of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL)

Dr CostasYannakou

Lymphoma in pregnant patients: the Australian experience

A retrospective data project in collaboration with St Vincent’s Hospital Sydney

This retrospective data project collected clinical information from patients diagnosed with Hodgkin or non-Hodgkin lymphoma during pregnancy or within 12 months postpartum, including a survey of diagnosis, treatment and care experiences

Patients diagnosed with Hodgkin or non-Hodgkin lymphoma during pregnancy or within 12 months postpartum

Dr CostasYannakou

Patterns of care and survival outcomes in relapsed or refractory mantle cell lymphoma (MCL) in Australia.

Retrospective project in collaboration with Peter MacCallum Cancer Centre

This retrospective project aims to describe characteristics of the R/R MCL cohort, with aim to develop effective and tolerable treatments. Data was collected from a number of Epworth patients over a short period of time; data is currently under analysis with Peter MacCallum Cancer Centre.

Patients with relapsed or refractory mantle cell lymphoma (MCL)

Dr CostasYannakou
Are you a researcher?

Find out how we can support you 

Referrals

Submit a referral for your patient

Support us

Make a donation

Your support allows us to continue our work on innovative treatments for people with blood cancers. Your donation will go directly to patient care, research and clinical trials.

Donate online